nach oben

Current Psychiatry Reports

Erschienen in:

01.07.2015 | Child and Adolescent Disorders (T Benton, Section Editor)

Assessment and Treatment of Anxiety Disorders in Children and Adolescents

verfasst von: Anna M. Wehry, Katja Beesdo-Baum, Meghann M. Hennelly, Sucheta D. Connolly, Jeffrey R. Strawn

Erschienen in: Current Psychiatry Reports | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Recent advances in the developmental epidemiology, neurobiology, and treatment of pediatric anxiety disorders have increased our understanding of these conditions and herald improved outcomes for affected children and adolescents. This article reviews the current epidemiology, longitudinal trajectory, and neurobiology of anxiety disorders in youth. Additionally, we summarize the current evidence for both psychotherapeutic and psychopharmacologic treatments of fear-based anxiety disorders (e.g., generalized, social, and separation anxiety disorders) in children and adolescents. Current data suggest that these disorders begin in childhood and adolescence, exhibit homotypic continuity, and increase the risk of secondary anxiety and mood disorders. Psychopharmacologic trials involving selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SSNRIs) are effective in pediatric patients with anxiety disorders and have generally demonstrated moderate effect sizes. Additionally, current data support cognitive behavioral therapy (CBT) for the treatment of these conditions in youth and suggest that the combination of psychotherapy + an SSRI may be associated with greater improvement than would be expected with either treatment as monotherapy.

Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.PubMedCentralPubMedCrossRef

Merikangas KR, He JP, Burnstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–9.PubMedCentralPubMedCrossRef

Foley DL, Goldston DB, Costello EJ, Angold A. Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains study. Arch Gen Psychiatry. 2006;63:1017–24.PubMedCrossRef

Jacobson CM, Muehlenkamp JJ, Miller AL, Turner JB. Psychiatric impairment among adolescents engaging in different types of deliberate self-harm. J Clin Child Adolesc Psychol. 2008;37(2):363–75.PubMedCrossRef

Beesdo-Baum K, Pine DS, Lieb R, Wittchen J. Mental disorders in adolescence and young adulthood: homotypic and heterotypic longitudinal associations. American College of Neuropsychopharmacology 51^st Annual Meeting, Hollywood, Florida, 2012.

Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998;55(1):56–64.PubMedCrossRef

Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–66.PubMedCentralPubMedCrossRef

Beesdo K, Pine DS, Lieb R, Wittchen H-U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67(1):47–57.PubMedCrossRef

Blackford JU, Pine DS. Neural substrates of childhood anxiety disorders: a review of neuroimaging findings. Child Adolesc Psychiatr Clin N Am. 2012;21(3):501–25.PubMedCentralPubMedCrossRef

10.

Strawn JR, Wehry AM, DelBello MP, Rynn MA, Strakowski S. Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety. 2012;29:328–39.PubMedCrossRef

11.

Kendall PC, Compton SN, Walkup JT, Birmaher B, Albano AM, Sherrill J, et al. Clinical characteristics of anxiety disordered youth. J Anxiety Disord. 2010;24(3):36–5.CrossRef

12.

Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin N Am. 2009;32:483–524.CrossRef

13.

Costello EJ, Copeland W, Angold A. Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults? J Child Psychol Psychiatry. 2011;52(10):1015–25.PubMedCentralPubMedCrossRef

14.•

Beesdo-Baum K, Knappe S. Developmental epidemiology of anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2012;21(3):457–78. This paper describes the emergence and trajectory of anxiety disorders over the lifespan in children, adolescents and young adults.PubMedCrossRef

15.

Bittner A, Egger HL, Erkanli A, Costello EJ, Foley DL, Angold A. What do childhood anxiety disorders predict? J Child Psychol Psychiatry. 2007;48(12):1174–83.PubMedCrossRef

16.

Copeland WE, Shanahan L, Costello J, Angold A. Childhood and adolescent psychiatric disorders as predictors of young adult disorders. Arch Gen Psychiatry. 2009;66(7):764–72.PubMedCentralPubMedCrossRef

17.

Woodward LJ, Fergusson DM. Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40(9):1086–93.PubMedCrossRef

18.

Gregory AM, Caspi A, Moffitt TE, Koenen K, Eley TC, Poulton R. Juvenile mental health histories of adults with anxiety disorders. Am J Psychiatry. 2007;164(2):301–8.PubMedCrossRef

19.

Wittchen H-U, Lieb R, Pfister H, Schuster P. The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. Compr Psychiatry. 2000;41: 2, Suppl 1:122-132.

20.

Zimmermann P, Wittchen H-U, Höfler M, Pfister H, Kessler RC, Lieb R. Primary anxiety disorders and the development of subsequent alcohol use disorder: a 4-year community study of adolescents and young adults. Psychol Med. 2003;33(7):1211–22.PubMedCrossRef

21.

Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007;64(8):903–12.PubMedCrossRef

22.

Wittchen H-U, Kessler RC, Pfister H, Lieb R. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000;406:14–23.PubMedCrossRef

23.

Bittner A, Goodwin RD, Wittchen HU, Beesdo K, Hofler M, Lieb R. What characteristics of primary anxiety disorders predict subsequent major depressive disorder? J Clin Psychiatry. 2004;65(5):618–26.PubMedCrossRef

24.

Shear MK, Bjelland I, Beesdo K, Gloster AT, Wittchen H-U. Supplementary dimensional assessment in anxiety disorders. Int J Methods Psychiatr Res. 2007;16(Suppl1):S52–64.PubMedCrossRef

25.

Wittchen H-U, Knappe S, Schumann G. The psychological perspective on mental health and mental disorder research: introduction to the ROAMER work package 5 consensus document. Int J Methods Psychiatr Res. 2014;23(S1):15–27.PubMedCrossRef

26.

Copeland WE, Angold A, Shanahan L, Costello EJ. Longitudinal patterns of anxiety from childhood to adulthood: the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2014;53(1):21–33.PubMedCentralPubMedCrossRef

27.

Beesdo-Baum K, Lieb R, Wittchen H-U. Anxiety disorders as early stages of malignant psychopathological long-term outcomes: results of the 10-years prospective EDSP study. Compr Psychiatry. 2013;54(8):e16.CrossRef

28.

Strawn JR, Dominick KC, Patino LR, Doyle CD, Picard PS, Phan KL. Neurobiology of pediatric anxiety disorders. Curr Behav Neurosci Rep. 2014;1(3):154–60.PubMedCentralPubMedCrossRef

29.

Maslowsky J, Mogg K, Bradley BP, McClure-Tone E, Ernst M, Pine DS, et al. A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol. 2010;20(2):105–11.PubMedCentralPubMedCrossRef

30.

McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ, et al. Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry. 2007;64(1):97–106.PubMedCrossRef

31.

Strawn JR, Bitter SM, Weber WA, Chu WJ, Whitsel RM, Adler C, et al. Neurocircuitry of generalized anxiety disorder in adolescents: a pilot functional neuroimaging and functional connectivity study. Depress Anxiety. 2012;29(11):939–47.PubMedCrossRef

32.

American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:267–83.CrossRef

33.

March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(4):554–65.PubMedCrossRef

34.

Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1230–6.PubMedCrossRef

35.

Spence SH. A measure of anxiety symptoms among children. Behav Res Ther. 1998;36:545–66.PubMedCrossRef

36.

Velting ON, Setzer NJ, Albano AM. Update and advances in assessment and cognitive-behavioral treatment of anxiety disorders in children and adolescents. Prof Psychol Res Pract. 2004;35:42–54.CrossRef

37.

Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1061–9.CrossRef

38.

Möller E, Majdandzic M, Craske MG, Bögels S. Dimensional assessment of anxiety disorders in parents and children for DSM-5. Int J Methods Psychiatr Res. 2014;23(3):331–44.PubMedCrossRef

39.

Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1622–32.PubMedCrossRef

40.•

Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, et al. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014;53:297–310. This analyses describes long-term outcomes following an acute, double-blind, placebo-controlled trial of sertraline, CBT or sertraline + CBT.PubMedCentralPubMedCrossRef

41.

Ginsburg GS, Becker EM, Keeton CP, Sakolsky D, Piacentini J, Albnano AM, et al. Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry. 2014;71(3):310–8.PubMedCentralPubMedCrossRef

42.

Hirschfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-Wurman RA, McQuade J, et al. Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. J Consult Clin Psychol. 2010;78(4):498–510.CrossRef

43.

Zgierska A, Rabago D, Chawla N, Kushner K, Koehler R, Marlatt A. Mindfulness meditation for substance use disorders: a systematic review. Subst Abus. 2009;30(4):266–94.PubMedCentralPubMedCrossRef

44.

Burke CA. Mindfulness-based approaches with children and adolescents: a preliminary review of current research in an emergent field. J Child Fam Stud. 2010;19(2):133–44.CrossRef

45.

Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, et al. Effectiveness of mindfulness‐based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009;26(7):601–6.PubMedCrossRef

46.

Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013;74(8):786–92.PubMedCentralPubMedCrossRef

47.

Koszycki D, Benger M, Shlik J, Bradwejn J. Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007;45(10):2518–26.PubMedCrossRef

48.

Jazaieri H, Goldin PR, Werner K, Ziv M, Gross JJ. A randomized trial of MBSR versus aerobic exercise for social anxiety disorder. J Clin Psychol. 2012;68(7):715–31.PubMedCentralPubMedCrossRef

49.

Bögels SM, Sijbers GFVM, Voncken M. Mindfulness and task concentration training for social phobia: a pilot study. J Cogn Psychother. 2006;20(1):33–44.CrossRef

50.

Cassin SE, Rector NA. Mindfulness and the attenuation of post-event processing in social phobia: an experimental investigation. Cogn Behav Ther. 2011;40(4):267–78.PubMedCrossRef

51.

Hooper N, Davies N, Davies L, McHugh L. Comparing thought suppression and mindfulness as coping techniques for spider fear. Conscious Cogn. 2011;20(4):1824–30.PubMedCrossRef

52.

Vøllestad J, Sivertsen B, Nielsen GH. Mindfulness-based stress reduction for patients with anxiety disorders: evaluation in a randomized controlled trial. Behav Res Ther. 2011;49(4):281–8.PubMedCrossRef

53.

Arch JJ, Ayers CR, Baker A, Almklov E, Dean DJ, Craske MG. Randomized clinical trial of adapted mindfulness-based stress reduction versus group cognitive behavioral therapy for heterogeneous anxiety disorders. Behav Res Ther. 2013;51(4):185–96.PubMedCrossRef

54.

Kocovski NL, Fleming JE, Hawley LL, Huta V, Antony MM. Mindfulness and acceptance-based group therapy versus traditional cognitive behavioral group therapy for social anxiety disorder: a randomized controlled trial.". Behav Res Ther. 2013;51(12):889–98.PubMedCrossRef

55.

Catani C, Kohiladevy M, Ruf M, Schauer E, Elbert T, Neuner F. Treating children traumatized by war and Tsunami: a comparison between exposure therapy and meditation-relaxation in North-East Sri Lanka. BMC Psychiatry. 2009;9:22.PubMedCentralPubMedCrossRef

56.

Liehr P, Diaz N. A pilot study examining the effect of mindfulness on depression and anxiety for minority children. Arch Psychiatr Nurs. 2010;24(1):69–71.PubMedCrossRef

57.

Göttken T, White LO, Klein AM, von Klitzing K. Short-term psychoanalytic child therapy for anxious children: a pilot study. Psychotherapy (Chic). 2014;51(1):148–58.CrossRef

58.

Fonagy P, Target M. Predictors of outcome in child psychoanalysis: a retrospective study of 763 cases at the Anna Freud Centre. J Am Psychoanal Assoc. 1996;44(1):27–77.PubMed

59.

Kiser RS, Lebovitz RM. Monoaminergic mechanisms in aversive brain stimulation. Physiol Behav. 1975;15(1):47–53.PubMedCrossRef

60.

Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415–23.PubMedCrossRef

61.

Research Units on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344(17):1279–85.CrossRef

62.

Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153–62.PubMedCrossRef

63.

Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008–14.PubMedCrossRef

64.

Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007;164(2):290–300.PubMedCrossRef

65.

March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62(10):1149–54.PubMedCrossRef

66.•

Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL. A randomized, placebo-controlled study of duloxetine for the treatment of children (7-11 years) and adolescents (12-17 years) with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(4):283–93. This recent article describes the registration trial for the only USFDA approved antidepressant for GAD in children and adolescents.

67.•

Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–57. This article represents the only meta-analysis of antidepressants in pediatric patients with non-OCD anxiety disorders and also examines treatment-emergent side effect profiles.PubMedCrossRef

68.

Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry. 1992;31(1):29–33.PubMedCrossRef

69.

Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33(3):372–6.PubMedCrossRef

70.

Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119–27.PubMedCrossRef

71.

Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011;79(6):806–13.PubMedCentralPubMedCrossRef

72.

Masi G, Pfanner C, Mucci M, Berloffa S, Magazu A, Parolin G, et al. Pediatric social anxiety disorder: predictors of response to pharmacological treatment. J Child Adolesc Psychopharmacol. 2012;22(6):410–4.PubMedCrossRef

73.•

Compton SN, Peris TS, Almirall D, Birmaher B, Sherrill J, Kendall PC, et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol. 2014;82(2):212–24. A recent analysis of clinical and demographic factors which are associated with differential response to psychopharmacologic and psychotherapeutic response in pediatric patients with anxiety disorders.PubMedCentralPubMedCrossRef

74.

Gittelman-Klein R, Klein DF. Controlled imipramine treatment of social phobia. Arch Gen Psychiatry. 1971;25(3):204–7.CrossRef

75.

Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry. 1992;31(1):21–8.PubMedCrossRef

76.

Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000;39(3):276–83.PubMedCrossRef

Titel: Assessment and Treatment of Anxiety Disorders in Children and Adolescents
verfasst von: Anna M. Wehry
Katja Beesdo-Baum
Meghann M. Hennelly
Sucheta D. Connolly
Jeffrey R. Strawn
Publikationsdatum: 01.07.2015
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 7/2015
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-015-0591-z

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Sexual Assault in the Military

Neuroimaging and Sexual Behavior: Identification of Regional and Functional Differences

Children’s Disaster Reactions: the Influence of Family and Social Factors

New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments